Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares, rose in value, with the stock price up by 2.03% to the previous day’s close as strong demand from buyers drove the stock to $35.69.
Actively observing the price movement in the last trading, the stock closed the session at $34.98, falling within a range of $34.743 and $35.74. The value of beta (5-year monthly) was 0.607. Referring to stock’s 52-week performance, its high was $60.37, and the low was $29.59. On the whole, RARE has fluctuated by -10.06% over the past month.
With the market capitalization of Ultragenyx Pharmaceutical Inc currently standing at about $3.35 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-12.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 655.81M, with a low estimate of 127M and a high estimate of 165.4M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 144.42M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RARE’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of RARE currently trading nearly 0.50% and -8.81% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.65, while the 7-day volatility ratio is showing 3.78% which for the 30-day chart, stands at 5.61%. Furthermore, Ultragenyx Pharmaceutical Inc (RARE)’s beta value is 0.35, and its average true range (ATR) is 1.91.
A comparison of Ultragenyx Pharmaceutical Inc (RARE) with its peers suggests the former has fared considerably weaker in the market. RARE showed an intraday change of 2.03% in last session, and over the past year, it shrunk by -15.65%%.
Data on historical trading for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) indicates that the trading volumes over the past 10 days have averaged 1.18 and over the past 3 months, they’ve averaged 809.89K. According to company’s latest data on outstanding shares, there are 92.41 million shares outstanding.
Nearly 6.75% of Ultragenyx Pharmaceutical Inc’s shares belong to company insiders and institutional investors own 94.06% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.53 million shares as on 2025-03-31, resulting in a short ratio of 6.0. According to the data, the short interest in Ultragenyx Pharmaceutical Inc (RARE) stood at 499.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 4.59 million. The stock has fallen by -15.17% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RARE stock heading into the next quarter.
